An Evaluation of Selected Populations for HIV-1 Vaccine Cohort Development in Nigeria

Development of a globally effective HIV-1 vaccine will need to encompass Nigeria, one of the hardest hit areas, with an estimated 3.2 million people living with HIV. This cross-sectional Institutional Review Board (IRB) approved study was conducted in 2009–12 at four market sites and two highway set...

Descripción completa

Detalles Bibliográficos
Autores principales: Njoku, Ogbonnaya S., Manak, Mark M., O’Connell, Robert J., Shutt, Ashley L. W., Malia, Jennifer A., Heipertz, Richard A., Tovanabutra, Sodsai, Milazzo, Mark J., Akintunde, Gideon Akindiran, Alabi, Abraham S., Suleiman, Aminu, Ogundeji, Amos A., Kene, Terfa S., Nelson, Robbie, Ayemoba, Ojor R., Singer, Darrell E., Robb, Merlin L., Peel, Sheila A., Michael, Nelson L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5147844/
https://www.ncbi.nlm.nih.gov/pubmed/27936236
http://dx.doi.org/10.1371/journal.pone.0166711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5147844/
https://www.ncbi.nlm.nih.gov/pubmed/27936236
http://dx.doi.org/10.1371/journal.pone.0166711

Ejemplares similares